TG Therapeutics Inc (TGTX)
16.54
+0.34
(+2.13%)
USD |
NASDAQ |
May 06, 16:00
16.16
-0.38
(-2.27%)
After-Hours: 20:00
TG Therapeutics Research and Development Expense (Quarterly): 32.72M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 32.72M |
| December 31, 2023 | 17.45M |
| September 30, 2023 | 14.75M |
| June 30, 2023 | 28.12M |
| March 31, 2023 | 15.87M |
| December 31, 2022 | 29.64M |
| September 30, 2022 | 20.80M |
| June 30, 2022 | 26.87M |
| March 31, 2022 | 48.04M |
| December 31, 2021 | 62.65M |
| September 30, 2021 | 51.97M |
| June 30, 2021 | 44.87M |
| March 31, 2021 | 63.09M |
| December 31, 2020 | 42.96M |
| September 30, 2020 | 50.46M |
| June 30, 2020 | 36.45M |
| March 31, 2020 | 36.02M |
| December 31, 2019 | 30.94M |
| September 30, 2019 | 57.98M |
| June 30, 2019 | 32.87M |
| March 31, 2019 | 32.38M |
| December 31, 2018 | 52.28M |
| September 30, 2018 | 33.40M |
| June 30, 2018 | 38.70M |
| March 31, 2018 | 35.02M |
| Date | Value |
|---|---|
| December 31, 2017 | 26.00M |
| September 30, 2017 | 27.15M |
| June 30, 2017 | 26.71M |
| March 31, 2017 | 22.68M |
| December 31, 2016 | 22.28M |
| September 30, 2016 | 21.80M |
| June 30, 2016 | 13.53M |
| March 31, 2016 | 11.62M |
| December 31, 2015 | 15.25M |
| September 30, 2015 | 11.57M |
| June 30, 2015 | 11.26M |
| March 31, 2015 | 9.617M |
| December 31, 2014 | 15.14M |
| September 30, 2014 | 13.69M |
| June 30, 2014 | 6.848M |
| March 31, 2014 | 4.410M |
| December 31, 2013 | 3.756M |
| September 30, 2013 | 3.310M |
| June 30, 2013 | 5.028M |
| March 31, 2013 | 1.570M |
| December 31, 2012 | 1.080M |
| September 30, 2012 | 1.561M |
| June 30, 2012 | 1.646M |
| March 31, 2012 | 16.74M |
| December 31, 2011 | 0.0143M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
14.75M
Minimum
Sep 2023
63.09M
Maximum
Mar 2021
37.23M
Average
34.44M
Median
Research and Development Expense (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 35.03M |
| Geron Corp | 29.37M |
| Editas Medicine Inc | 69.56M |
| G1 Therapeutics Inc | 7.38M |
| Mersana Therapeutics Inc | 21.50M |